Oxford’s Covid-19 vaccine has created a lot of anticipation. It is heard that it has succeeded in the initial stage examination.
In India, the vaccine is called the Covi shield (ChAdOx1 nCoV-19).
In India, it is being made by the Serum Institute of India (CII) in Pune.
In terms of numbers, the world’s largest pharmaceutical company estimates that in low- and middle-income countries, including India, each dose will cost around Rs 225, or a maximum of 3 dollars.
The Serum Institute recently announced a new far-reaching agreement with Gavi.
The Vaccine made with Alliance and The Bill & Melinda Gates Foundation.
Aimed at rapidly producing the potential Covid-19 vaccine for a larger number of India and low-income countries.
They will manufacture and supply up to 100 million doses.
Adar Punawala, CEO of the Serum Institute, thanked the Bill & Melinda Gates Foundation and Gavie for sharing the risk and tying up 100 million doses of the potential Covid-19 vaccine.
As a result of this understanding, an equal number of vaccines will be available in many countries, and prices will be affordable.
Recently, the Drug Controller General of India (DCGI) allowed the Serum Institute to conduct second and third phase trials of vaccines made by Oxford University in India.
The vaccine, developed by Oxford and AstraZeneca, is now in its final stages in Britain, Brazil, and in South Africa.
ChAdOx1 nCoV-19 is one of the most promising vaccines for the prevention of the novel coronavirus.
According to The Lancet magazine, it was first tested experimentally in the human body, it developed strong immunity, and posed no safety hazard.
The World Health Organization (WHO) has confirmed that six vaccines running for recognition against the novel coronavirus have entered the third round of trials.
Other than the Oxford AstraZeneca vaccine, Modern / NIAID, Biotech / Fosan Pharma / Pfizer, Synovac, Wuhan Institute of Biological Products / Synoform, and Beijing Institute of Biological Products / Sinofo.
Read More – Oxford vaccine results positive, Serum Institute wants a trial in India Oxford
A whole world waiting for lunch fast coronavirus vaccine and available in the market.